Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic

Christian Karagiannidis1*, Arthur S. Slutsky2, Thomas Bein3, Wolfram Windisch1, Steffen Weber-Carstens4 and Daniel Brodie5

Research Letter

Extracorporeal membrane-oxygenation (ECMO) has been widely used for COVID-19-related acute respiratory distress syndrome (ARDS), with a mortality rate of 37.1% based on the largest published series [1]. This rate is comparable to ECMO-supported patients with non-COVID-19-related ARDS [1]. However, some reports suggest that the real-life mortality is higher than that reported above [2], including a cohort of 768 COVID-19 patients in Germany with an in-hospital mortality rate of 73% [3], and a surprising finding is given that health care resources in Germany were not notably under strain during the pandemic. To better characterize this discrepancy, we evaluated in-hospital mortality for all COVID-19 patients in Germany supported with venovenous ECMO (VV-ECMO).

We report unbiased and unselected follow-up data at hospital discharge from the federal German hospital payment institute (InEK) of all 3,397 COVID-19 patients supported with VV-ECMO in Germany from March 1st, 2020, through May 31st, 2021. ECMO in Germany was provided in 213 intensive care units (ICUs)—out of a total of 1,684 intensive care units across 1,288 hospitals (www.intensivregister.de). The study was approved by the Ethics Committee of the Witten/Herdecke University.

The mean age of all ECMO patients remained stable over the study period (57 ± 11 years). As expected, survivors were younger than the non-survivors (53 years (range 47–63 y) vs. 59y (Range: 54-63y)), independent of timing during the pandemic. To better characterize this discrepancy, we evaluated in-hospital mortality for all COVID-19 patients in Germany supported with venovenous ECMO (VV-ECMO).

We report unbiased and unselected follow-up data at hospital discharge from the federal German hospital payment institute (InEK) of all 3,397 COVID-19 patients supported with VV-ECMO in Germany from March 1st, 2020, through May 31st, 2021. ECMO in Germany was provided in 213 intensive care units (ICUs)—out of a total of 1,684 intensive care units across 1,288 hospitals (www.intensivregister.de). The study was approved by the Ethics Committee of the Witten/Herdecke University.

The mean age of all ECMO patients remained stable over the study period (57 ± 11 years). As expected, survivors were younger than the non-survivors (53 years (range 47–63 y) vs. 59y (Range: 54-63y)), independent of timing during the pandemic. The mean duration of ECMO support was not different between survivors and non-survivors, averaging 17 days. Overall, in-hospital mortality was 68%. Of note, the mortality for any given week (Fig. 1) shows some degree of variation, as survivors spend more time in hospital than non-survivors.

In the largest unbiased and unselected real-life cohort reported to date of VV-ECMO-supported patients with COVID-19-related respiratory failure, we found that in-hospital mortality for patients in Germany was 68%. This is markedly higher than that reported from other countries or from international registries [2–5], confirming prior results [3] of a higher mortality rate in Germany than reported elsewhere.

Mortality in ECMO-supported COVID-19 patients may be increasing over the course of the pandemic, as reported in the most recent Extracorporeal Life Support Organization (ELSO) cohort with a mortality of 51.9% in patients initiated on ECMO after May 1, 2020 [5]. However, that is still lower than the present cohort from Germany. One explanation is the older mean age of

*Correspondence:  Christian.Karagiannidis@uni-wh.de; karagiannidisc@kliniken-koeln.de
1 Department of Pneumology and Critical Care Medicine, ARDS and ECMO Centre, Cologne-Merheim Hospital, Kliniken Der Stadt Köln gGmbH, Witten/Herdecke University Hospital, Ostmerheimer Strasse 200, 51109 Cologne, Germany
Full list of author information is available at the end of the article

© The Author(s) 2021, corrected publication 2022
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
57 ± 11 years in our report compared to the ELSO report (median 51 years). Another explanation is that the use of ECMO in Germany is not centrally regulated and clinicians could elect to initiate ECMO without constraints from regulatory bodies, potentially extending criteria beyond those patients who would be likely to benefit. Furthermore, in Germany, there is an incentive system for the control of health care which is characterized by proportional reimbursement: “as more procedures are done, as more will be paid by insurances,” probably leading to a mixture of “true” indications and reimbursement temptations [6]. A comprehensive central case registry would be particularly important during a pandemic to frequently analyze data and draw updated conclusions. Finally, the ELSO data represent dedicated ECMO centers, whereas the current data are unselected from all German hospitals.

A major strength of the study is inclusion of every COVID-19 patient treated with VV-ECMO in Germany (population ~ 83,000,000) over the course of the study. One limitation is the lack of granularity of the data, including comorbidities, impairing our ability to better understand the reasons for the high mortality.

Ultimately, the present data should serve as a warning to clinicians. Even in a country with adequate resources, mortality in ECMO-supported patients with COVID-19-related respiratory failure may be high if its use is not restricted to patients deemed most likely to benefit.

Acknowledgements
We are very grateful to the federal German hospital payment institute (InEK, Institut für das Entgeltsystem im Krankenhaus) for their outstanding work.

Authors’ contributions
CK is responsible for the data integrity and analyzed the data together with all authors. CK and DB wrote the main draft of the manuscript. All authors had full access to the data. All authors contributed to interpretation and writing of the manuscript and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data materials
Not applicable.

Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Witten/Herdecke University.

Consent for publication
All authors approved the final draft of the manuscript and gave their consent for publication.

Competing interests
CK reports personal fees from Maquet, personal fees from Xenios, personal fees from Bayer, non-financial support from Speaker of the German register of ICUs, grants from the German Ministry of Research and Education, during the conduct of the study. TB, WW and SWC have nothing to disclose. AS reports personal fees from Baxter and Xenios in relation to consulting with respect to ECMO. DB receives research support from ALung Technologies. He has been on the medical advisory boards for Baxter, Abiomed, Xenios and Cellenkos.

Author details
1 Department of Pneumology and Critical Care Medicine, ARDS and ECMO Centre, Cologne-Merheim Hospital, Kliniken Der Stadt Köln gGmbH, Witten/Herdecke University Hospital, Ostermerheimer Strasse 200, 51109 Cologne, Germany. 2 Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St Michael’s Hospital University of Toronto, Toronto, Canada. 3 Faculty of Medicine, University of Regensburg, Regensburg, Germany. 4 Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin, Berlin, Germany. 5 Department of Medicine, Columbia University College of Physicians and Surgeons, and the Center for Acute Respiratory Failure, New York-Presbyterian Hospital, New York, USA.

Received: 29 October 2021 Accepted: 17 November 2021

Published online: 29 November 2021

References
1. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021;25(1):211.
2. Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med 2021.
3. Karagiannidis C, Strassmann S, Merten M, et al. High in-hospital mortality in COVID patients receiving ECMO in Germany - A critical analysis. Am J Respir Crit Care Med 2021.
4. Broman LM, Ekborg S, Coco VL, et al. Extracorporeal membrane oxygenation for COVID-19 during first and second waves. Lancet Respir Med 2021.
5. Barbaro RP MG, Boonstra PS, Combis A, Agerstrand CL, Annich G, Diaz R, Fan E, Hryniewicz K, Lorusso R, Paden ML, Stead CM, Swol J, Iwashyna TJ, Slutsky AS, Brodie D; for the Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation for COVID-19: Evolving outcomes from the international Extracorporeal Life Support Organization Registry. Lancet Respir Med 2021; (in press August 19).
6. Friedrichson B, Mutlak H, Zacharowski K, Piekarski F. Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. Crit Care. 2021;25(1):38.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.